Opinion

Video

The MOA of TLX250

Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with zirconium for radiographic detection.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      The Novel Tracer 89Zr-TLX250

      Main Discussion Topics:

      • 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX).
      • CAIX is an enzyme expressed on the surface of most clear cell renal cell carcinomas (ccRCCs).
      • The antibody is coupled to zirconium-89, a positron emitter detectable on PET imaging.

      Key Points for Physicians:

      • The tracer targets CAIX, which is highly expressed in ccRCC.
      • The mechanism of action involves antibody binding coupled with a radioactive tracer.
      • Zirconium-89 serves as the positron-emitting component for detection.

      Notable Insights:

      The targeting of CAIX represents a specific molecular approach to identifying ccRCC based on its unique expression pattern.

      Clinical Significance:

      This targeted molecular approach represents a fundamental shift from anatomic to biological characterization of renal masses.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      © 2025 MJH Life Sciences

      All rights reserved.